Abstract
Many immunotherapy approaches including therapeutic cancer vaccines targeting specific tumor-associated antigens are at various stages of development. Although the significance of overexpression of (IL-13Rα2) in cancer is being actively investigated, we have reported that IL-13Rα2 is a novel tumor-associated antigen. The IL-13Rα2-directed cancer vaccine is one of the most promising approaches to tumor immunotherapy, because of the selective expression of IL-13Rα2 in various solid tumor types but not in normal tissues. In this article, we will summarize its present status and potential strategies to improve IL-13Rα2-directed cancer vaccines for an optimal therapy of cancer.
MeSH terms
-
Animals
-
Antigens, Neoplasm / immunology
-
Cancer Vaccines / genetics
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use*
-
Drug Therapy, Combination
-
Humans
-
Immunosuppression Therapy
-
Immunotherapy / methods*
-
Immunotoxins / administration & dosage
-
Immunotoxins / immunology*
-
Interleukin-13 Receptor alpha2 Subunit / genetics
-
Interleukin-13 Receptor alpha2 Subunit / immunology*
-
Interleukin-13 Receptor alpha2 Subunit / metabolism
-
Lymphocyte Activation
-
Mice
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Vaccines, DNA / genetics
-
Vaccines, DNA / immunology
-
Vaccines, DNA / therapeutic use
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Immunotoxins
-
Interleukin-13 Receptor alpha2 Subunit
-
Vaccines, DNA